Phenylketonuria (PKU) management practices differ between and within countries. In 2007, the Portuguese Society for Metabolic Disorders (SPDM) approved the Portuguese Consensus (PC) for the nutritional treatment of PKU. The recently published European PKU Guidelines (EPG, 2017) systematically reviewed recent evidence and aimed to harmonise treatment protocols in Europe. The objective of this study was to appraise the EPG acceptance and implementation in Portuguese treatment centres.
An electronic questionnaire was prepared and the link was sent to 135 SPDM members. It outlined the 10 EPG key recommendations and compared each statement with the consensus recommendations published by SPDM. Responses were recorded and descriptive analyses were performed.
Twenty-five professionals completed the questionnaire, and over half (56%) were nutritionists/dieticians. At least one questionnaire from each of the 10 national treatment centres was returned. In general, responders accepted most of the recommendations. However, only the recommendation about target phenylalanine (Phe) concentrations between 120 and 360 μmol/L for patients <12 years received 100% consensus with a further seven recommendations gaining over 70% consensus. Almost half of the professionals (48%, n = 12) required further discussion about the EPG-safe upper target blood Phe concentration (600 μmol/L) suggested for patients aged ≥12 years. Almost one third (32%, n = 8) failed to agree with the recommendation in the EPG-proposed classification of Phe hydroxylase (PAH) deficiency.
The EPG received overall good acceptance, but there was divided opinion about some recommendations which require further discussion before implementation by the Portuguese treatment centres.
The authors thank the Portuguese Society of Metabolic Disorders for supporting this study.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: Manuela Ferreira Almeida received grants from Glutamine, Nutricia, Merck Serono, Biomarin, Orphan and Lifediet to attend congress and for education. Anita MacDonald received research funding and honoraria from Nutricia, Vitaflo International and Merck Serono. She is a member of the European Nutritionist Expert Panel [Biomarin], member of Sapropterin Advisory Board [Biomarin], member of the Advisory Board entitled ELEMENT [Danone-Nutricia], and member of an Advisory Board for Arla and Applied Pharma Research. Júlio César Rocha is a member of the European Nutritionist Expert Panel [Biomarin], member of an Advisory Board for Applied Pharma Research s.a. and Nutricia. He received speaker fees from APR, Merck Serono, Biomarin, Nutricia, Vitaflo and Cambrooke.
3. Vilarinho L, Diogo L, Pinho e Costa P. Programa Nacional de Diagnóstico Precoce: relatório 2015. Instituto Nacional de Saúde Doutor Ricardo Jorge, IP 2016.Search in Google Scholar
4. Al Hafid N, Christodoulou J. Phenylketonuria : a review of current and future treatments. Transl Pediatr 2015;4:304–17.Search in Google Scholar
5. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin [BH4] deficiencies. Mol Genet Metab 2011;104(Suppl):S2–9.10.1016/j.ymgme.2011.08.017Search in Google Scholar
6. van Spronsen FJ, van Wegberg AM, Ahring K, Bélanger-Quintana A, Blau N, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol 2017;5:743–56.10.1016/S2213-8587(16)30320-5Search in Google Scholar
7. Rocha JC, Vilarinho L, Cabral A, Osório RV, Almeida MF.Consensus for the nutritional treatment of phenylketonuria. Acta Pediatr Port 2007;38:44–54.Search in Google Scholar
8. Pena MJ, De Almeida MF, Van Dam E, Ahring K, Bélanger-Quintana A, et al. Protein substitutes for phenylketonuria in Europe: access and nutritional composition. Eur J Clin Nutr 2016;70:785–9.10.1038/ejcn.2016.54Search in Google Scholar
9. Pena MJ, Almeida MF, Van Dam E, Ahring K, Bélanger-Quintana A, et al. Special low protein foods for phenylketonuria: availability in Europe and an examination of their nutritional profile. Orphanet J Rare Dis 2015;10:162.10.1186/s13023-015-0378-7Search in Google Scholar
10. Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet 2002;360:55–7.10.1016/S0140-6736(02)09334-0Search in Google Scholar
11. Tansek MZ, Groselj U, Kelvisar M, Kobe H, Lampret BR, et al. Long-term BH4 (sapropterin) treatment of children with hyperphenylalaninemia – effect on median Phe/Tyr ratios. J Pediatr Endocrinol Metab 2016;29:561–6.10.1515/jpem-2015-0337Search in Google Scholar PubMed
12. Cockburn F, Barwell BE, Brenton DP, Chapple J, Clark B, et al. Recommendations on the dietary management of phenylketonuria. Arch Dis Child 1993;68:426–7.10.1136/adc.68.3.426Search in Google Scholar PubMed PubMed Central
14. Panel N. Phenylketonuria: screening and management. NIH Consens Statement Online 2000;17:1–27.Search in Google Scholar
15. Abadie V, Berthelot J, Feillet F, Maurin N, Mercier A, et al. [Management of phenylketonuria and hyperphenylalaninemia: the French guidelines]. Arch Pediatr 2005;12:594–601.10.1016/j.arcped.2005.02.004Search in Google Scholar PubMed
16. Ahring K, Bélanger-Quintana A, Dokoupil K, Ozel HG, Lammardo AM, et al. Dietary management practices in phenylketonuria across European centres. Clin Nutr 2009;28:231–6.10.1016/j.clnu.2009.03.004Search in Google Scholar PubMed
18. Hagedorn TS, Van Berkel P, Hammerschmidt G, Lhotáková M, Saludes RP. Requirements for a minimum standard of care for phenylketonuria: the patients’ perspective. Orphanet J Rare Dis 2013;8:191.10.1186/1750-1172-8-191Search in Google Scholar PubMed PubMed Central
19. Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, et al. Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab 2010;99:109–15.10.1016/j.ymgme.2009.09.005Search in Google Scholar PubMed
20. Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med 2014;16:188–200.10.1038/gim.2013.157Search in Google Scholar PubMed
21. Singh RH, Rohr F, Frazier D, Cunningham A, Mofidi S, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 2014;16:121–31.10.1038/gim.2013.179Search in Google Scholar PubMed PubMed Central
22. Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, et al. Updated, web-based nutrition management guideline for PKU: an evidence and consensus based approach. Mol Genet Metab 2016;118:72–83.10.1016/j.ymgme.2016.04.008Search in Google Scholar PubMed
23. van Spronsen FJ, Ahring KK, Gizewska M. PKU – What is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders. J Inherit Metab Dis 2009;32:58–64.10.1007/s10545-008-0966-ySearch in Google Scholar PubMed
24. Morris AA, Kožich V, Santra S, Andria G, Ben-Omran TI, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 2017;40:49–74.10.1007/s10545-016-9979-0Search in Google Scholar PubMed PubMed Central
25. Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012;7:32.10.1186/1750-1172-7-32Search in Google Scholar PubMed PubMed Central
26. Boy N, Mühlhausen C, Maier EM, Heringer J, Assmann B, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis 2017;40:75–101.10.1007/s10545-016-9999-9Search in Google Scholar PubMed
27. Häberle J, Huemer M. Evaluation of implementation, adaptation and use of the recently proposed urea cycle disorders guidelines. JIMD Rep 2015;21:65–70.10.1007/8904_2014_387Search in Google Scholar PubMed PubMed Central
28. Rocha JC, MacDonald A. Dietary intervention in the management of phenylketonuria: current perspectives. Pediatr Heal Med Ther 2016;7:155–63.10.2147/PHMT.S49329Search in Google Scholar PubMed PubMed Central
29. Boot E, Hollak CE, Huijbregts SC, Jahja R, Van Vliet D, et al. Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria. Psychol Med 2017;47:2854–65.10.1017/S0033291717001398Search in Google Scholar PubMed
30. Jahja R, Huijbregts SC, de Sonneville LM, van der Meere JJ, Legemaat AM, et al. Cognitive profile and mental health in adult phenylketonuria: a PKU-COBESO study. Neuropsychology 2017;31:437–47.10.1037/neu0000358Search in Google Scholar PubMed
31. Berry SA, Brown C, Grant M, Greene CL, Jurecki E, et al. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med 2013;15:591–9.10.1038/gim.2013.10Search in Google Scholar PubMed PubMed Central
33. Fonnesbeck CJ, McPheeters ML, Krishnaswami S, Lindegren ML, Reimschisel T. Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis. J Inherit Metab Dis 2013;36:757–66.10.1007/s10545-012-9564-0Search in Google Scholar PubMed
34. Jahja R, Huijbregts SC, De Sonneville LM, Van Der Meere JJ, Van Spronsen FJ. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr 2014;164:895–99.e2.10.1016/j.jpeds.2013.12.015Search in Google Scholar PubMed
35. Weglage J, Pietsch M, Feldmann R, Koch HG, Zschocke J, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res 2001;49:532–6.10.1203/00006450-200104000-00015Search in Google Scholar
36. Smith ML, Saltzman J, Klim P, Hanley WB, Feigenbaum A, et al. Neuropsychological function in mild hyperphenylalaninemia. Am J Ment Retard 2000;105:69–80.10.1352/0895-8017(2000)105<0069:NFIMH>2.0.CO;2Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston